Magenta Therapeutics (MGTA) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MGTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MGTA, but not buy additional shares or sell existing shares.
View MGTA analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 1-year price targets for Magenta Therapeutics' stock. Their MGTA share price forecasts range from $1.00 to $3.00. On average, they anticipate the company's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 212.5% from the stock's current price.
View analysts price targets for MGTA or view top-rated stocks among Wall Street analysts.

Magenta Therapeutics' stock was trading at $0.3950 at the beginning of 2023. Since then, MGTA stock has increased by 62.0% and is now trading at $0.64.
View the best growth stocks for 2023 here.

Magenta Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 408,800 shares, a decline of 56.0% from the April 30th total of 930,000 shares. Based on an average daily volume of 514,400 shares, the short-interest ratio is currently 0.8 days. Approximately 0.9% of the shares of the stock are sold short.
View Magenta Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 29th 2023.
View our MGTA earnings forecast.

Magenta Therapeutics, Inc. (NASDAQ:MGTA) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.03.

Harbor Disruptive Innovation ETF holds 40,742 shares of MGTA stock, representing 0.10% of its portfolio.

3 employees have rated Magenta Therapeutics Chief Executive Officer Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among the company's employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP).

(MGTA) raised $100 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Magenta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (6.25%), TCW Group Inc. (1.24%), Acadian Asset Management LLC (1.01%), Renaissance Technologies LLC (0.65%), RBF Capital LLC (0.41%) and Susquehanna International Group LLP (0.30%). Insiders that own company stock include Bruce Booth, Kristen Stants and Rock Ventures Iv LP Third.
View institutional ownership trends.

Shares of MGTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MGTA stock can currently be purchased for approximately $0.64.

Magenta Therapeutics (NASDAQ:MGTA) has a market capitalization of $38.82 million. The company earns $-76,460,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.magentatx.com. The company can be reached via phone at (857) 201-2700 or via email at investor@magentatx.com.